Xencor, Inc. (XNCR) News
Filter XNCR News Items
XNCR News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
XNCR News Highlights
- For XNCR, its 30 day story count is now at 4.
- Over the past 22 days, the trend for XNCR's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about XNCR are FC.
Latest XNCR News From Around the Web
Below are the latest news stories about XENCOR INC that investors may wish to consider to help them evaluate XNCR as an investment opportunity.
Xencor Presents Clinical Results from Phase 1a Study of XmAb®564 at the EULAR 2023 CongressPASADENA, Calif., May 30, 2023--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases, today announced the presentation of results from its Phase 1a single-ascending dose study of XmAb®564 in healthy volunteers. XmAb564 is a potency-tuned IL-2-Fc fusion protein, engineered to selectively activate and expand regulatory T cells (Tregs) for the potential treatment of pat |
Q1 2023 Xencor Inc Earnings CallQ1 2023 Xencor Inc Earnings Call |
Xencor (XNCR) Reports Q1 Loss, Tops Revenue EstimatesXencor (XNCR) delivered earnings and revenue surprises of -36% and 1.10%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock? |
Xencor Reports First Quarter 2023 Financial ResultsPASADENA, Calif., May 08, 2023--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases, today reported financial results for the first quarter ended March 31, 2023 and provided a review of recent business and clinical highlights. |
Xencor to Host First Quarter 2023 Financial Results Webcast and Conference Call on May 8, 2023PASADENA, Calif., May 01, 2023--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced it will release first quarter 2023 financial results after the market closes on Monday, May 8, 2023. |
Xencor Appoints Nancy Valente, M.D., as Chief Development OfficerPASADENA, Calif., April 26, 2023--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the appointment of Nancy Valente, M.D., to Executive Vice President, Chief Development Officer. Dr. Valente has more than 20 years of experience in late-stage biopharmaceutical product development, and she most recently served as a senior vice president at Genentech, a member of |
Xencor Highlights CD28 Bispecific Antibody Platform at AACR Annual Meeting 2023PASADENA, Calif., April 17, 2023--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today presented new preclinical data generated from engineered CD28 bispecific antibodies targeting the solid tumor antigens CEACAM5, ENPP3, mesothelin, STEAP1 and Trop-2. For each molecule, in vitro T cell activation was enhanced in combination with a CD3 T cell engager. The data were presente |
7 Biotech Stocks to Buy for 100% ReturnsIf you can handle the risks associated with high volatility, these biotech stocks to buy might double the returns in your portfolio. |
Xencor to Present Preclinical Data from Novel XmAb® CD28 Bispecific Antibody Programs at the American Association for Cancer Research Annual Meeting 2023PASADENA, Calif., March 14, 2023--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced it will present preclinical data on novel XmAb® CD28 bispecific antibody programs at the American Association for Cancer Research (AACR) Annual Meeting, being held April 14-19, 2023 at the Orange County Convention Center in Orlando, Florida. |
Strength Seen in Xencor (XNCR): Can Its 5.3% Jump Turn into More Strength?Xencor (XNCR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road. |